Algeta
Alpha-emitter anticancer agents
Algeta developed Xofigo® (radium-223 dichloride), a first-in-class, targeted alpha-pharmaceutical that was approved by the US FDA and European EMA for treatment of patients with symptomatic bone metastases secondary to castration-resistant prostate cancer.
CEO Andrew Kay
Advent Contact Shahzad Malik
Advent invested in the Series A in 2005. Algeta listed on the Oslo Stock exchange in March 2007 and was acquired by Bayer in 2014 for $2.9B.
Exited Investments
Bayer commences voluntary cash offer to acquire the entire issued share capital of Algeta
Press Release. Oslo, Norway, 20 January, 2014 - Algeta ASA ("Algeta"; OSE: ALGETA) today announced that Aviator Acquisition AS, a wholly-owned subsidiary of Bayer Nordic SE, has commenced the…
Read More
The Board of Directors of Algeta ASA unanimously recommends voluntary cash offer from Bayer to acquire the entire issued share capital of Algeta
Press Release. Not intended for US media Offer at NOK 362 per Algeta share, in cash, valuing the total share capital of Algeta at approximately NOK 17.6 billion (USD…
Read More
Algeta announces that Xofigo® (radium-223 dichloride) has been approved by the US FDA
Press Release. New treatment for castration-resistant prostate cancer (CRPC) patients with bone metastases Xofigo shown in a pivotal phase III trial to significantly improve overall survival Algeta to host…
Read More
Algeta’s partner Bayer submits New Drug Application to US FDA for Radium-223 Dichloride
Press Release. Oslo, Norway, 14 December 2012 - Algeta ASA (OSE: ALGETA) announces that Bayer has submitted a New Drug Application (NDA) to the US Food and Drug Administration…
Read More
Algeta’s partner Bayer submits Radium-223 Dichloride for EU Marketing Authorisation
Press Release. Oslo, Norway, 12 December 2012 - Algeta ASA (OSE: ALGETA) announces that Bayer has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for…
Read More
Positive Outcome for Algeta in Pivotal Alpharadin Study
Press Release. Positive Outcome of Interim Analysis of pivotal Alpharadin study: Primary endpoint met in Phase III ALSYMPCA study. Alpharadin is in development for treating bone metastases in patients…
Read More
Algeta wins Scrip Award for Biotechnology Company of the Year
Press Release. Scrip's Biotech Company of the Year award seeks to acknowledge the vital importance to the industry of biotechnology’s cutting-edge science and entrepreneurial spirit. This year, from a…
Read More
Algeta concludes agreements for the manufacture and supply of Alpharadin for future commercial sale
Press Release. Oslo, Norway - Algeta ASA (OSE: ALGETA), the focused oncology company, today has announced it has concluded two agreements for the manufacture and supply of Alpharadin for…
Read More
New phase II data presented at ECCO 15 and 34th ESMO Congress reinforces exciting potential of Algeta’s Alpharadin as a new treatment for bone metastases in cancer patients
Press Release. Oslo, Norway, 22 September 2009 - Algeta ASA (OSE:ALGETA), the cancer therapeutics company, announces that new clinical data from three phase II clinical trials with Alpharadin have been…
Read More
Algeta – Magic Bullet is my Weapon
Press Release. http://www.dailyexpress.co.uk/posts/view/110873/Magic-bullet-is-my-weapon
Read More
Algeta Reports Positive Headline Phase II Data on Pain Palliation with Alpharadin
Press Release. Oslo, Norway, 28 August 2008 - Algeta ASA (OSE: ALGETA), the Norwegian cancer therapeutics company, today announced that the primary objective of its BC1-03 Phase II pain…
Read More
Algeta receives IND Approval for Alpharadin(TM) to commence Clinical Development in the USA
Press Release. Oslo, Norway, 21 February 2008 - Algeta ASA (OSE: ALGETA), the cancer therapeutics company, today announced that it will shortly commence clinical development of Alpharadin(TM) in HRPC…
Read More
Algeta provides update on its late-stage clinical programme for Alpharadin in prostate cancer
Press Release. Oslo, Norway, 20 December 2007 - Algeta ASA (OSE: ALGETA), the cancer therapeutics company, is pleased to provide an update on its clinical development of Alpharadin in…
Read More
Alpharadin treatment more than doubles survival rate in prostate cancer patients
Press Release. Algeta presents new Phase II clinical trial data at ECCO Oslo, Norway, 25 September 2007 - Algeta ASA (OSE: ALGETA), the Norwegian cancer therapeutics company, today…
Read More
Algeta’s Phase II Clinical Study Data for Alpharadin™ in Prostate Cancer Published in Lancet Oncology
Press Release. Oslo, Norway, 4 June 2007 - Algeta ASA (OSE: ALGETA), the Norwegian cancer therapeutics company, is pleased to announce that clinical Phase II study data for Alpharadin™…
Read More
